Yuyu Pharma

유유제약 · 000220

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$46.2M (₩63.7B)

Overview

Yuyu Pharma makes prescription medicines and health-supplement products for human use, and supplies finished pharmaceuticals to hospitals and clinics across South Korea.

It also manufactures medicines on a contract basis for other domestic pharmaceutical companies and exports finished drug products to markets in Southeast Asia, Latin America, and beyond. Listed on KOSPI, South Korea's main stock exchange, the company operates through several subsidiaries covering health-supplement manufacturing, medical-device distribution, veterinary drug research, and pet-health products.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$102.1M

▲ +5.8% YoY

Operating profit · FY2025

US$8M

▼ −5.8% YoY

Net income · FY2025

US$6.6M

▼ −11.4% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$99.4M(₩137.2B)	US$96.5M(₩133.1B)	US$102.1M(₩140.9B)
Operating profit	US$264.2K(₩364.5M)	US$8.5M(₩11.7B)	US$8M(₩11B)
Net income	−US$4M(−₩5.5B)	US$7.5M(₩10.3B)	US$6.6M(₩9.1B)

Revenue

FY2023US$99.4M
FY2024US$96.5M
FY2025US$102.1M

Operating profit

FY2023US$264.2K
FY2024US$8.5M
FY2025US$8M

Net income

FY2023−US$4M
FY2024US$7.5M
FY2025US$6.6M

Key ratios (FY2025)

ROE

6.5%

Debt/Eq

47.4%

Op. margin

7.8%

Net margin

6.5%

Rev. YoY

▲ +5.8%

Why it matters

Its subsidiaries include US-based entities, YUYU VENTURES, YUYU BIO, and MERVYNS PETCARE, extending the group's footprint into veterinary drug research and pet-health products in the United States.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?